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Tetrahydropentagamavunon-0 (THPGV-0) and Tetrahydro-
pentagamavunon-1 (THPGV-1), are analogs of a curcumin 
metabolite, tetrahydrocurcumin, and a derivate of Pentagama-
vunon-0 (PGV-0) and Pentagamavunon-1 (PGV-1), respectively.  
THPGV-0 and THPGV-1 have been successfully synthesized and 
are investigated for their anticancer potency.  Cytotoxic assays 
were performed toward several cancer cell lines to determine 
values of IC50. Assessing cytotoxicity on Vero normal cell line 
showed the selectivity of those compound.  THPGV-1 showed 
highest cytotoxic activity in lymphoma Raji cells, a suspension 
cell line, with an IC50 of 180µM.  Both THPGV-0 and THPGV-1 
showed similar potencies on T47D breast cancer cell line with 
IC50 values of 250-270µM. Regardless their high selectivity, 
however, cytotoxic activities of THPGV-0 and THPGV-1 were 
lower compared to PGV-0 and PGV-1 on HeLa cervical, T47D 
breast, and WiDr colon cancer cell lines.  Further study using 
different types of cancer cell lines and confirmation of cell 
viability by another assays and apoptosis detection may give 
more benefit. 
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INTRODUCTION  
Curcumin (Figure 1) is a well-known 
natural compound isolated from the rhizome of 
turmeric (Curcuma longa) and famous for its 
antioxidant and anti-inflammatory properties 
(Aggarwal et al, 2005). More interestingly, 
curcumin also possesses anticancer potency as 
it is able to inhibit the growth of several types 
of cancer cells (reviewed by Aggarwal et al., 
2005).  Curcumin as anticancer has been draw 
the attention of researchers to work in this             
field aimed to elucidate its mechanism.  
Recently, curcumin has been confirmed for                 
its antitumorigenic in vivo and reported to target 
reactive oxygen species metabolic pathway to 
suppress tumor cell growth (Larasati et al, 
2018). 
 
Inspired by curcumin, Faculty of 
Pharmacy Universitas Gadjah Mada (UGM) has 
been challenged to discover and synthesize 
novel curcumin analogs which possess                
higher biological activity than curcumin itself.   
In 2004, at least two compounds namely                
PGV-0 and PGV-1 (Figure 1) were patented 
(Reksohadiprodjo et al., 2004).  Indeed, PGV-0 
and PGV-1 not only show higher antioxidant 
and anti-inflammatory effects, but also higher 
anticancer potencies on several cancer cell lines 
(Table I). 
Table I presents the anticancer potencies 
of curcumin, PGV-0, and PGV-1 indicated by 
their cytotoxic activities toward cancer cell lines 
through IC50 values.  IC50 is the inhibitory 
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concentration for 50% cell population and is 
used as an early parameter for anticancer 
screenings (Doyle and Griffiths, 2000). In 
addition of cancer cell lines (Table I), cytotoxic 
activity of PGV-0 on lymphoma Raji (Dai, 
2003), HeLa cervical cancer (Meiyanto et al., 
2003) and myeloma cells (Dai et al., 2004), were 
also have been identified. Remarkably, these 
analog compounds are more selective to 
normal cells compared to curcumin, indicated 
by higher IC50 values toward Vero normal cell 
line (Marbawati and Sardjiman, 2015; Safitri, 
2017). 
The most challenging obstacle of 
curcumin or its analogs for in vivo application is 
due to its poor bioavailability.  Tetrahydro-
curcumin (THC) (Figure 1) is the major 
curcumin   metabolite   after  biotransformation  
 
process, more stable than its parent compound, 
and responsible for the biological activities of 
curcumin in the body (Nugroho, 2006). 
Addition of four hydroxil species increases the 
solubility of the compound. 
Analogs of THC and derivates of PGV-0 
and PGV-1 namely THPGV-0 (Ritmaleni and 
Simbara, 2010) and THPGV-1 (Ritmaleni et al., 
2013a; Ritmaleni et al., 2013b) has been 
synthesized. Both compounds biologically active 
as shown by their antihistamine (Nugroho et al., 
2010), antibacterial (Ritmaleni et al., 2013b), and 
antifungal (Ritmaleni et al., 2016) activities.  
This current study investigated anticancer 
potency of THPGV-0 and THPGV-1 by 
determining their IC50 values on several cancer 
cell lines.  Equally important, the selectivity 
toward normal cells was also examined. 
 
  
        
 
                   
 
                            
 
Figure 1. Structure of curcumin, PGV-0, PGV-1, THC, THPGV-0, and THPGV-1 
 
Table I. Cytotoxic activity (IC50 µM) of PGV-0 and PGV-1 on several cancer cell lines 
 
Cell line Curcumin  PGV-0  PGV-1  Reference 
T47D breast_ 21.6 10.9 - Meiyanto et al., 2006a 
 - 9.39 1.74 Dai et al., 2007 
T47D + estradiol 19.8 6.85 - Nurulita and Meiyanto, 2006 
T47D/estrogen 19.1 - 3.16 Meiyanto et al., 2006b 
WiDr colon 27 45 8 Septisetyani et al., 2008 
MCF-7 breast - 50 6 Hermawan et al., 2011 
MCF-7/HER2 82 80 21 Meiyanto et al., 2014 
CT26 colon 93.1 73.4 47.6   Safitri, 2017 
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MATERIAL AND METHODS 
Materials 
THPGV-0 and THPGV-1 was 
synthesized according to the previous 
published methods (Ritmaleni and Simbara, 
2010 and Ritmaleni et al, 2013a, respectively).  
The detail of synthesis can be found in 
Ritmaleni et al, 2013b.  Besides being tested for 
their cytotoxic activity as comparison, PGV-0 
and PGV-1 as the starting materials were 
obtained from Curcumin Research Center, 
Faculty of Pharmacy Universitas Gadjah              
Mada (UGM).  The compounds were initially 
dissolved in dimethyl sulfoxide (DMSO, 99.5% 
pro-GC, Sigma Aldrich) for stock solutions. 
 
Cell culture 
HeLa cervical cancer, lymphoma Raji, 
T47D breast cancer, and Vero normal cell lines 
were obtained from Integrated Laboratory of 
Research and Testing (Laboratorium Penelitian 
dan Pengujian Terpadu, LPPT) UGM.  WiDr 
colon cancer cell line was a collection of Cancer 
Chemoprevention Research Center, Faculty of 
Pharmacy UGM.  Cells were grown in media, 
RPMI 1640 (Gibco) for cancer cells or in M199 
(Gibco) for Vero cells, supplemented with 10% 
(v/v) fetal bovine serum (FBS, Gibco), 1% 
(v/v) penicillin-streptomycin (Gibco), and 1% 
(v/v) Fungizon (Gibco) and cultured in the 
CO2 incubator at 37°C.  At around 80% 
confluence, the attached cell types (HeLa, 
T47D, WiDr, and Vero) were harvested with 
trypsinization by using 0.025% trypsin-EDTA 
(Gibco).  Harvested cells were used thereafter 
for assays.  Cell culture and cytotoxicity study 
were performed in LPPT UGM. 
 
Cell viability assay 
Cell viability assays by using MTT 
method (Itagaki et al, 1998) were carried out to 
determine the cytotoxic activity.  The cells were 
distributed into the 96-well plate, incubated for 
24h, and then treated with various 
concentrations of the compounds for another 
24h.  The serial concentrations (7.8; 15.6; 31.25; 
62.5; 125; 250; 500; and 1,000g/mL) were 
prepared from stock solutions and serially 
diluted in the appropriate culture medium.  
MTT assays for attached cell lines and MTT 
assay for Raji suspension cell line were 
performed according to the previous 
publications (Septisetyani et al, 2008 and Astuti 
et al, 2004, respectively), and carried out in 
triplicate.  The absorbance at 595 nm of diluted 
formazan after addition of MTT (3-(4,                     
5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium 
bromide) (Sigma Aldrich) reagent and stopper 
solutions (10% SDS (Merck) in 0.1N HCl 
(Merck)) were measured by an ELISA reader 
(Biorad). Untreated cells were served as control, 
while well without cells was served as blank. 
 
Data analysis 
The percentage of cell viability was 
defined as (absorbance of treated cells - 
absorbance of blank)/(absorbance of control - 
absorbance of blank) x 100%, and were used to 
calculate IC50 values by a linear regression 
analysis: cell viability (%, y axis) vs log 
concentration (µg/mL, x axis) (Doyle and 
Griffiths, 2000).  IC50 values were converted 
into molar. 
 
RESULT AND DISCUSSION 
Cytotoxicity of THPGV-0 and THPGV-1 
on several cancer cell lines 
Treatment of THPGV-0 and THPGV-1 
decreased percentage of cancer cell viability in a 
dose-dependent manner (Figure 2). Both 
THPGV-0 and THPGV-1 showed similar 
cytotoxic activity in attached type of cancer cell 
lines (HeLa, T47D, and WiDr), but THPGV-1 
decreased the viability of Raji cells, a 
suspension type of cell cancer, more efficiently 
than THPGV-0 (Figure 2).  To further measure 
the anticancer potency of THPGV-0 and 
THPGV-1, IC50 values were calculated by using 
a linear regression analysis.  The linear 
regression is presented in table II and IC50 
values are listed in table III. 
THPGV-0 and THPGV-1 possessed 
equal IC50 values for HeLa and T47D cells and 
quite close values for WiDr cells.  Somehow, 
on Raji cells, THPGV-1 showed much more 
potent cytotoxicity, almost six times higher, 
compared to THPGV-0. 
To confirm previous findings and             
also to minimalize the false negative conclusion 
due to difference of several variables                      
(i.e. compound source, laboratory facilities,           
cell culture system, methodology, etc), we            
also re-investigated cytotoxicity of PGV-0 and          
PGV-1 at the same time (Table II and Table III).   
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Figure 2. Cytotoxicity of THPGV-0 and THPGV-1 on several cancer cell lines.  Cells were treated 
with a serial concentration of THPGV-0 (black circle) or THPGV-1 (white square) for 24h, and then 
were assayed by MTT method in triplicate.  Graphics of logarithm (log) of concentration versus 
percentage of cell viability for each cancer cell lines are presented as indicated.  Dashed line marked 
50% of cell viability.  The graphics demonstrated the phenomenon of dose-dependent cytotoxicity. 
 




Line equation, cell viability vs log concentration (µg/mL) (linearity, r)* 
HeLa Raji T47D WiDr 
THGPV-0 
y = -55.85x+ 
173.54 (0.903) 
y = -45.591x+ 
167.55 (0.847) 
y = -54.76x+ 
142.3 (0.853) 
y = -45.23x+ 
143.9 (0.909) 
THGPV-1 
y = -55.556x+ 
169.82 (0.979) 
y = -64.413x+ 
165.89 (0.885) 
y = -56.62x+ 
143.3 (0.925) 
y = -33.02x+ 
129.1 (0.922) 
PGV-0 
y = -55.58x+ 
170.40 (0.903) 
y = -19.712x+ 
102.49 (0.904) 
y = -55.27x+ 
130.8 (0.923) 
y = -35.88x+ 
113.6 (0.912) 
PGV-1 
y = -25.901x+ 
96.281 (0.948) 
- y = -31.74x+ 
72.76 (0.988) 
y = -17.31x+ 
78.90 (0.995) 
 
*The cell viability was measured by MTT assay in triplicate for each compounds on each cell lines. 
 
Table III. Cytotoxic activity (IC50 µM) of THPGV-0 and THPGV-1 on several cancer cell lines*. 
 
Compound HeLa Raji T47D WiDr 
THGPV-0 460 1.070 270 330 
THGPV-1 410 180 250 570 
PGV-0 200 1.300 170 170 
PGV-1 170 - 30 130 
 
*The cell viability was measured by MTT assay in triplicate for each compounds on each cell lines and IC50 
values were calculated. 
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 Agreed with previous reports, PGV-1 was 
always more potent than PGV-0 on HeLa, 
T47D, and WiDr cells.  Unfortunately, due to 
our limitation, we failed to obtain PGV-1 data 
in Raji cells. Nevertheless, we can conclude that 
in general THPGV-0 and THPGV-1 possessed 
less potent cytotoxicity compared to PGV-0 
and PGV-1, at least on above-tested cancer cell 
lines (Table III). 
 
Selectivity of THPGV-0 and THPGV-1 
toward Vero normal cell line 
Vero cell line was used as a model for 
normal cells.  The MTT assays revealed that 
even at the highest concentration of THPGV-0 
or THPGV-1 (1.000g/mL), the cell viability 
was more than 80% (Figure 3).  Since 50% of 
cell viability was never reached during 
treatment, the IC50 value was not calculated nor 
extrapolated (Table IV).  It can be concluded 
that THPGV-0 and THPGV-1 were selective 
on Vero normal cells. 
Again, to confirm previous findings, the 
parent compound was also tested (Table IV).  
PGV-0 was also selective on Vero cells. As PGV-
1 is more potent than PGV-0, further 





Our current study investigated the 
anticancer potency of THPGV-0 and THPGV-
1, a derivate of PGV-0 and PGV-1, 
respectively, by determining the IC50 values in 
vitro.  We showed that THPGV-0 and THPGV-
1 are equally selective on Vero normal cells, but 
THPGV-1 is more potent than THPGV-0 on 
cancer cells.  This corresponds well with 
previously reported findings of the parent 
compounds, in which PGV-1 possesses more 
potent anticancer activity than PGV-0 on 
T47D and MCF-7 breast cancer cell lines (Dai 
et al, 2007; Hermawan et al, 2011), metastatic 
 
 
Figure 3. Selectivity of THPGV-0 and THPGV-1 on Vero normal cell line.  Cells were treated with 
a serial concentration of THPGV-0 (black circle) or THPGV-1 (white square) for 24 h, and then were 
assayed by MTT method in triplicate.  Graphics of logarithm (log) of concentration versus 
percentage of cell viability is presented.  Dashed line marked 50% of cell viability. 
 
Table IV. Selectivity of THPGV-0 and THPGV-1 on Vero normal cell line. 
 
Compound 




Concentration Cell viability* 
THGPV-0 y = 6.36x+91.83 0.461 696µM >80% 
THGPV-1 y = -1.9508x+104.22 0.125 1.404µM >80% 
PGV-0 y = -11.64x+101.00 0.867 1.465µM >100% 
 
*The cell viability was measured by MTT assay in triplicate for each compounds. 
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breast cancer cells MCF-7/HER2 (Meiyanto et 
al, 2014), and on WiDr and CT26 colon cancer 
cell lines (Septisetyani et al, 2008; Safitri, 2017). 
In this study, we only used one normal 
cell line as the model and were not able to 
calculate the SI (Table IV).  However, the 
selectivity toward other types of normal cell 
lines as well as normal primary cell cultures is 
also important to be further evaluated. One 
parameter that can be used to assess selectivity 
of tested compounds is selectivity index (SI), as 
introduced by previous reports (Popiolkiewicz 
et al, 2005; Pena-Moran et al, 2016).  Pena-
Moran et al (2016) describe SI as the value of 
IC50 of normal cells divided by IC50 of cancer 
cells, and a SI≥10 is considered belongs to a 
selective compound. 
Those above-mentioned cancer cell lines 
are attached type.  However, THPGV-1 
exhibits highest cytotoxic activity in lymphoma 
Raji cells, a suspension type cell.  Regrettably, in 
this study we did not have an IC50 value of 
PGV-1 on Raji cells, thus we cannot draw a 
further conclusion to measure the potency of 
THPGV-1 compared to PGV-1.  Nonetheless, 
further screening of THPGV-1 anticancer 
properties compared to PGV-1 on suspension 
cancer cell lines will give more beneficial 
information. 
To confirm the MTT result, another 
methods to detect cell viability than such 
colorimetric assay based on the reduction by 
living cells of tetrazolium salt (Mosmann, 1983) 
can be carried out.  To mention few examples 
are a manual direct counting, infrared assay 
using nuclei and cytosol staining or cytoskeletal 
antibodies, and luminescence assay for ATP 
(Posimo et al, 2014).  Nonetheless, the IC50 
value is only one parameter among several 
parameters of anticancer potency. Another 
important parameter to be investigated is the 
potency of apoptotic induction.  Indeed, 
previous reports have been successfully showed 
that the parent compound, PGV-0 and PGV-1, 
induce apoptosis more efficiently than 
curcumin on several cancer cell line: T47D 
(Nurulita and Meiyanto, 2006; Meiyanto et al, 
2006b; Meiyanto et al, 2007), WiDr 
(Septisetyani et al, 2008), and MCF-7 
(Hermawan et al, 2011). 
Regarding the structure-activity 
relationship, the ,-unsaturated carbonyl is 
crucial for the cytotoxic activity (Sardjiman, 
2018; private communication).  Compared to 
the parent compound PGV-0 or PGV-1, 
THPGV-0 or THPGV-1 (Figure 1) loss the 
double bonds in the , position of carbonyl, 
resulting the decrease of electrophilicity of C 
carbonyl.  The positive charge of the above-
mentioned C carbonyl is weaker to result 
cytotoxic activity compared to the ,-
unsaturated carbonyl.  On the other hand, 
antioxidant or antibacterial properties are 
depends on the hydroxyl group or the presence 
of electron withdrawing groups in the orto 
position of the hydroxyl group, respectively 
(Sardjiman et al, 1997; Sardjiman, 2000). 
Therefore, both THPGV-0 and THPGV-1 
possess more potent antioxidant and 
antibacterial activities, but show less potent 
cytotoxic activity compared to their parent 
compounds. 
Regardless its low cytotoxicity, THPGV-
0 is promising to be developed as 
pharmaceutical compound accounts on its 
antioxidant property.  In fact, Ritmaleni and 
Murrukhmihadi have been doing quite 
extensive studies to develop THPGV-0 as anti-
aging agent for topical application (Ariella, 
2016; Putri, 2016; Alamsyah, 2016; Faharvia, 
2016; Krisdayani, 2016) due to its sun 
protecting factor (SPF) activity and little skin 
irritation risk in animal models (Febriana, 2016; 
Wastuwidya, 2017; Wulandari, 2017). 
More importantly, THPGV-1, the 
compound that possesses more potent 
cytotoxic than THPGV-0 but less potent than 
its parent compound, can be further developed 
as combinatorial agent for chemotherapy (co-
chemotherapy).  Co-chemotherapy is an 
approach for cancer therapy by combining 
clinically approved chemotherapeutic agents 
with less toxic compounds to enhance its 
efficacy and to reduce its toxicity to normal 
cells (Jenie and Meiyanto, 2007).  Former in vitro 
studies have been reported the effectiveness of 
this strategy toward several cancer cell lines, for 
example: combination of PGV-0 (Ikawati and 
Septisetyani, 2018) or PGV-1 (Septisetyani et al, 
2018) with 5-fluorouracil to sensitize WiDr 
cells, and combination of PGV-0 or PGV-1 
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with doxorubicin on MCF-7 cells (Hermawan et 




In general, THPGV-0 and THPGV-1 
exhibit lower cytotoxic activities compared to 
PGV-0 and PGV-1.  Regarding their relatively 
higher solubility, further investigation by using 
other suspension cell line types and other 
methods may give more clear information. 
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